Iterum Therapeutics plc (ITRMF) Net Equity Issued and Repurchased (2018 - 2025)

Iterum Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $5.4 million for Q3 2025.

• In Q3 2025, Net Equity Issued and Repurchased changed 0.24% year-over-year to $5.4 million; the TTM figure through Sep 2025 stood at $26.6 million (up 98.52% YoY), while the FY2024 annual figure was $26.7 million, up 2481.33% from the prior year.
• Net Equity Issued and Repurchased for Q3 2025 stood at $5.4 million, up from $957000.0 in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $13.9 million in Q4 2024, with the low at $10000.0 in Q3 2023.
• The 3-year median for Net Equity Issued and Repurchased is $957000.0 (2025), against an average of $3.7 million.
• Peak annual rise in Net Equity Issued and Repurchased reached 54200.0% in 2024, while the deepest fall reached 16.5% in 2024.
• Iterum Therapeutics' Net Equity Issued and Repurchased stood at $589000.0 in 2023, then soared by 2256.03% to $13.9 million in 2024, then tumbled by 60.96% to $5.4 million in 2025.
• Business Quant data shows ITRMF's Net Equity Issued and Repurchased at $5.4 million in Q3 2025, $957000.0 in Q2 2025, and $6.4 million in Q1 2025.